P. Le Coutre, O. G. Ottmann, F. Giles, D. W. Kim, J. Cortes, N. Gattermann, J. F. Apperley, R. A. Larson, E. Abruzzese, S. G. O’Brien, K. Kuliczkowski, A. Hochhaus, F. X. Mahon, G. Saglio, M. Gobbi, Y. L. Kwong, M. Baccarani, T. Hughes, G. Martinelli, J. P. Radich, M. Zheng, Y. Shou and H. Kantarjian, “Nilotinib (Formerly AMN107), a Highly Selective BCR/ABL1 Tyrosine Kinase Inhibitor, Is Active in Patients with Imatinib-Resistant or -Intolerant Accelerated-Phase Chronic Myemlogenous Leukemia,” Blood, Vol. 111, No. 4, 2008, pp. 1834-1839. doi:10.1182/blood-2007-04-083196

has been cited by the following article:

• TITLE: Mexican Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukaemia

  AUTHORS: Eduardo Cervera, Federico Godínez, Rosa Sosa, Ramón Rivas, Carlos Best, Juan Hernández, Adrián Morales, Hugo Zurita, Ivette Carrasco, Jorge Cruz, Álvaro Aguayo, José Espinoza, Juan Labardini, Luis Valero, Judith Cruz, Diana Arcos, Diego Limón, Omar López-Navarro, Daniela Gordillo-Bastidas, Myrna Candelaria, Francisco Torres, Juan Kassack, Oscar de Jesús Pérez Ramírez, Jorge Aquino, Guillermo Díaz, Mariela Cardiel, Margarita Rodríguez, Patricia Montoya, Juan Contreras, María Chávez, Sandra Chávez, David Gómez, Olga Cantú, Jorge Duque, Luis Pita, Eduardo Lobato, Julio López, Antonio López, Pedro González, Jorge Cortés

  KEYWORDS: Chronic Myeloid Leukaemia; Management Guidelines; Diagnosis; Treatment.

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.3, May 27, 2013

  ABSTRACT: Background: This document includes recommendations and guidelines issued by a group of Mexican researchers and specialists gathered in the First National Colloquium for the Diagnosis and Management of Chronic Myeloid Leukaemia (CML) by initiative of Instituto Nacional de Cancerología and with the support of the Leukaemia Department of the MD Anderson Cancer Center. Mexico lacks of updated information taken from its own reality on the diagnosis and treatment of CML and other haematological disorders; besides, there are no national guidelines. Aim: To publish a consensus document with guidelines for the management of CML adjusted to the national environment and overall characteristics. Method: The participants answered a DELPHI questionnaire about the overall aspects of the disease, aiming to target controversial topics, discuss them in the colloquium, and to agree on the best ones. After those meetings, a final document was drawn up. Results: The group presents recommendations for definition, diagnosis, prognosis, monitoring, and treatment of CML in Mexico. Conclusions: Having consensus guidelines for the clinical management of CML in our country will enable the consensual practice of Mexican specialists regarding the clinical approach to CML, as well as optimize the resources which allow the rational planning of the medical care strategies.